PastBook Raises $2 Million to Scale-Up its One-Click Photo Books Platform
PastBook, a fast-growing technology company specialized in frictionless photo book creation, announces today it has completed a new investment round of $2M, bringing the total amount raised by the company to over $2.5M.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921005099/en/
The investment was completed in two tranches: an initial convertible note plus a follow-up investment from existing investors (Vortex Capital Partners and other Dutch high net-worth individuals, mostly successful entrepreneurs).
According to investor Dinko Valerio - Founder and former CEO of Crucell, “As a sparring partner and investor, I am very pleased with the roll-out and success of PastBook. The company is clearly poised for further growth, which is why I am happy to continue my support.”
PastBook has been growing exponentially at a rate of 10x YoY in revenue for the last three years in a row, with the majority of customers (80%) being in the USA. The company will use the proceeds of the new investment round to introduce new products and fuel marketing activities for its international expansion through the launch of its Intelligent Instant Photo Book platform in several European countries – including The Netherlands, Germany, France, Italy and the UK – in addition to the USA, Australia and Canada where PastBook already has a significant commercial presence.
Stefano Cutello, Founder and CEO of PastBook says, “With our Intelligent Instant Photo Book solution focused on Facebook and Instagram, we have proven that we’re un-tapping a new segment in the market: people who always wanted to have a photo book but never found the time to make one. With the additional resources now at our disposal, we can go full-steam in developing solutions that cater to their needs.”
The PastBook Intelligent Instant Photo Book platform provides the most frictionless way to create a photo book from any source. PastBook’s own developed algorithm combines a huge range of data with smart technology to automatically select the user’s best photos (with their captions and dates) from a chosen time period and instantly arranges them into a photo book within 60 seconds, without requiring user interaction.
PastBook’s sophisticated technology and algorithms, combined with its one-click photo book creation engine, sets its service apart from its competitors and the more traditional, mainstream, players in the photo book market: 95% of the books sold by PastBook are instant books, i.e. not edited by its customers (having had the option to make changes). For 50% of the PastBook users, their PastBook photo book is the first photo book they have ever created.
PastBook also recently partnered up with RPI, a provider of premium quality photo book printing services with facilities in USA and Europe, along with partner facilities in Oceania. Through this partnership PastBook has been able to expand its global footprint and reduce shipping times.
ABOUT PASTBOOK - https://www.pastbook.com/
Founded in 2012 in Amsterdam, as part of RockStart Accelerator, PastBook has been named one of the ‘Hottest startup’s in Amsterdam” by Wired, nominated as “Rising Star” by Deloitte (Fast50) and listed as one of the “Top 5 Fastest Growing Tech Companies” by TheNextWeb (Tech5). It has also been featured by Facebook as Marketing Success Story (https://www.facebook.com/business/success/pastbook).
PastBook is on a mission to help people preserve and relive memories, that are nowadays scattered between social networks and devices, by offering the most frictionless experience to create a beautiful photo book in seconds.
PastBook’s Intelligent Instant Photo Book platform automatically and intelligently selects the best photos from designated and instantly arranges them into a beautiful photo book, ready to be printed.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Andersen Global Expands Presence in Germany with Addition of Thierhoff Müller & Partner13.12.2017 08:01 | Pressemelding
Andersen Global is proud to announce an expanded presence in Germany as Thierhoff Müller & Partner, a tax and legal firm with offices in Leipzig and Frankfurt, combines its practice with Andersen Tax & Legal in Germany. Through its German member firms, Andersen Tax & Legal and Alegis Steuerberatungsgesellschaft mbH, Andersen Global now has more than 65 professionals focused on providing tax and legal services and business advice across five locations in Germany, including Cologne, Dusseldorf, and Merzig. “Thierhoff Müller is highly regarded in complex restructuring matters. Together with our existing legal and tax practice, we will be able to increase our service offerings for our clients,” said Stefan Kraus, Managing Partner of Andersen Tax & Legal in Germany. “We are dedicated to providing outstanding service and are adding additional competencies in tax and legal such as corporate r
Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs13.12.2017 08:00 | Pressemelding
Aprecia Pharmaceuticals, LLC (“Aprecia”), The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. (“Cycle”) today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration. Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s
Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 16:07 | Pressemelding
Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s
Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00 | Pressemelding
Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid
Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33 | Pressemelding
Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom